Aigen Investment Management LP Lowers Holdings in Johnson & Johnson (NYSE:JNJ)

Aigen Investment Management LP trimmed its position in Johnson & Johnson (NYSE:JNJ) by 4.3% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 5,543 shares of the company’s stock after selling 250 shares during the quarter. Aigen Investment Management LP’s holdings in Johnson & Johnson were worth $919,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Highline Wealth Partners LLC lifted its holdings in shares of Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after buying an additional 86 shares during the period. von Borstel & Associates Inc. purchased a new stake in shares of Johnson & Johnson in the 1st quarter worth $49,000. Harvest Fund Management Co. Ltd purchased a new stake in shares of Johnson & Johnson in the 1st quarter worth $52,000. Capital A Wealth Management LLC purchased a new stake in shares of Johnson & Johnson in the 4th quarter worth $50,000. Finally, Pandora Wealth Inc. bought a new position in shares of Johnson & Johnson in the 1st quarter worth $65,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently commented on JNJ. Piper Sandler reissued an “overweight” rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Bank of America boosted their price target on Johnson & Johnson from $161.00 to $175.00 and gave the stock a “neutral” rating in a research report on Thursday, July 17th. UBS Group boosted their price target on Johnson & Johnson from $180.00 to $190.00 and gave the stock a “buy” rating in a research report on Thursday, July 17th. Sanford C. Bernstein reissued a “market perform” rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Finally, Erste Group Bank raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. Nine investment analysts have rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $174.50.

Johnson & Johnson Trading Up 1.1%

Shares of NYSE:JNJ opened at $173.40 on Monday. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $173.96. The company has a market capitalization of $417.61 billion, a PE ratio of 18.55, a PEG ratio of 2.21 and a beta of 0.41. The business has a 50 day moving average of $159.26 and a two-hundred day moving average of $157.60. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. Johnson & Johnson’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the previous year, the company posted $2.82 earnings per share. As a group, analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 3.0%. Johnson & Johnson’s dividend payout ratio is currently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.